Vcanbio Cell & Gene Engineering Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Vcanbio Cell & Gene Engineering has a total shareholder equity of CN¥3.7B and total debt of CN¥40.8M, which brings its debt-to-equity ratio to 1.1%. Its total assets and total liabilities are CN¥5.3B and CN¥1.6B respectively. Vcanbio Cell & Gene Engineering's EBIT is CN¥139.2M making its interest coverage ratio -5. It has cash and short-term investments of CN¥1.4B.
Anahtar bilgiler
1.1%
Borç/özkaynak oranı
CN¥40.76m
Borç
| Faiz karşılama oranı | -5x |
| Nakit | CN¥1.44b |
| Eşitlik | CN¥3.68b |
| Toplam yükümlülükler | CN¥1.60b |
| Toplam varlıklar | CN¥5.28b |
Son finansal sağlık güncellemeleri
Does Vcanbio Cell & Gene Engineering (SHSE:600645) Have A Healthy Balance Sheet?
Aug 26
Does Vcanbio Cell & Gene Engineering (SHSE:600645) Have A Healthy Balance Sheet?
May 24Recent updates
Vcanbio Cell & Gene Engineering Corp., Ltd's (SHSE:600645) Popularity With Investors Is Under Threat From Overpricing
Sep 27Does Vcanbio Cell & Gene Engineering (SHSE:600645) Have A Healthy Balance Sheet?
Aug 26Does Vcanbio Cell & Gene Engineering (SHSE:600645) Have A Healthy Balance Sheet?
May 24Vcanbio Cell & Gene Engineering's (SHSE:600645) Soft Earnings Are Actually Better Than They Appear
May 02Subdued Growth No Barrier To Vcanbio Cell & Gene Engineering Corp., Ltd's (SHSE:600645) Price
Apr 24Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 600645's short term assets (CN¥2.5B) exceed its short term liabilities (CN¥1.5B).
Uzun Vadeli Yükümlülükler: 600645's short term assets (CN¥2.5B) exceed its long term liabilities (CN¥118.8M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 600645 has more cash than its total debt.
Borcun Azaltılması: 600645's debt to equity ratio has reduced from 3.3% to 1.1% over the past 5 years.
Borç Kapsamı: 600645's debt is well covered by operating cash flow (713.3%).
Faiz Kapsamı: 600645 earns more interest than it pays, so coverage of interest payments is not a concern.